Soligenix, Inc. — Q2 2015 Form 10-Q
Reporting period: Three and six months ended June 30, 2015. Soligenix is a development-stage biopharmaceutical company with BioTherapeutics and Vaccines/BioDefense segments. Revenue was primarily from government contracts and grants; the filing reports no product sales.
Key financial metrics
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Revenue | $1.100 million | $1.418 million | $1.916 million | $2.329 million |
| Gross profit | $283,125 | $383,664 | $572,012 | $665,280 |
| Gross margin | 25.7% | 27.0% | 29.9% | 28.6% |
| Operating expenses | $2.318 million | $2.079 million | $4.165 million | $3.951 million |
| Net loss | $3.978 million | $948,517 | $8.547 million | $4.280 million |
| Net loss per share | $0.15 | $0.05 | $0.34 | $0.22 |
| Cash used in operating activities | Not separately presented quarterly | $3.716 million | $1.100 million |
- At June 30, cash and cash equivalents were $4.036 million, down from $5.525 million at December 31, 2014. Working capital was $2.328 million excluding the noncash warrant liability; total current liabilities were $8.886 million, including that $6.202 million liability.
- Total assets were $5.366 million and shareholders’ deficiency was $3.520 million. The balance sheet presents no borrowings or debt line item.
Material changes and unusual items
- Revenue declined 22% in Q2 and 18% for the six-month period, principally because the ThermoVax grant expired in Q4 2014. Grant revenue fell to $17,686 in Q2 2015 from $526,058 a year earlier.
- R&D expense increased 19% in Q2 and 10% for the six-month period, largely due to manufacturing clinical supplies for the planned Phase 3 SGX301 trial. Management attributed lower cash and working capital primarily to SGX942 trial spending and SGX301 manufacturing.
- Net loss included a noncash warrant fair-value charge of $1.943 million in Q2 and $4.955 million for six months, compared with a $746,992 gain in Q2 2014 and a $995,098 charge for the 2014 six-month period. The liability is remeasured and is affected by the company’s share price; it increased to $6.202 million from $3.790 million at year-end.
- Financing provided $2.240 million in the first half, including $1.115 million from the Lincoln Park equity line and $1.113 million from warrant exercises. Common shares outstanding rose to 26.375 million from 23.937 million at year-end.
Outlook, funding and risks
- Management said existing cash, anticipated government contract and grant proceeds, Lincoln Park facility availability, and New Jersey tax-certificate proceeds were expected to fund working capital and capital expenditures for at least 12 months from the filing date. This outlook depends on funding sources and execution; the filing warns that additional financing may not be available on favorable terms.
- Management estimated approximately $15.0 million of R&D expenditures over the next 12 months before grant reimbursements, including $5.3 million for BioTherapeutics and $9.7 million for Vaccines/BioDefense. It anticipated approximately $9.7 million of contract and grant revenue to offset Vaccines/BioDefense R&D expense.
- The company reported up to approximately $49.5 million in active government contract and grant funding available for associated programs, subject to contract terms and options. It also had approximately $8.4 million available under its $10.6 million Lincoln Park equity facility as of June 30, 2015.
- Pipeline plans included Phase 3 trials of SGX301 for CTCL and SGX203 for pediatric Crohn’s disease in the second half of 2015, and Phase 2 SGX942 data expected in the second half of 2015. These are forward-looking plans, not assured outcomes; several programs depend on continued government or other funding.
- On July 29, 2015, after quarter-end, the company agreed to sell up to $10 million of common stock to institutional investors from time to time. The resale registration statement was not yet effective as of the filing date.
- Commitments included approximately $500,000 for licensing agreements and $439,000 of property and other leases. Certain agreements may also require success-based milestone payments, including up to $7.9 million and royalties of up to 6% of covered-product net sales; a separate Hy Biopharma agreement provides for up to $10 million in milestone payments if achieved.
- Key risks include clinical and regulatory failure, reliance on government funding and external financing, potential dilution from equity issuance, and uncertainty around commercialization. Management reported effective disclosure controls and no additional risk factors beyond those in its 2014 Form 10-K.
Important facts for investors to verify
- Whether government contracts and grants are renewed, exercised, collected, and sufficient to support planned programs and projected spending.
- Actual cash runway and financing progress, including effectiveness and use of the July 2015 stock-purchase registration statement and remaining Lincoln Park capacity.
- Clinical-trial timing, enrollment, results, and funding for SGX301, SGX942, SGX203, and the biodefense programs.
- The effect of share-price changes and warrant terms on the $6.202 million warrant liability, reported earnings, and potential dilution.
- Whether milestone obligations, lease commitments, and other contractual payments change as development programs advance.